IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically me
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically me